What's behind Tempus AI's latest 3.5% stock pullback?

Traders Union
All News
Financial News
Tempus AI slides 3.51% to $47.26

Highlights

Tempus AI agreed to acquire Personalis, Inc. for approximately $1.5 billion to expand its precision medicine offerings.
The acquisition aims to strengthen Tempus' capabilities in minimal residual disease testing and biopharma data profiling, pending approvals.
Tempus AI trades under persistent downside momentum with strong bearish technical signals and a five-day expected price range of $42.01 to $52.51.

Acquisition-driven expansion faces persistent selling amid regulatory uncertainty

Tempus AI announced a definitive agreement to acquire Personalis, Inc. in a transaction valued at approximately $1.5 billion, with cash and stock components subject to certain price conditions. The transaction is intended to enhance Tempus' capabilities in minimal residual disease testing and biopharma data profiling, pending regulatory and shareholder approval. Additionally, Tempus launched the OneOme 27-Gene Pharmacogenomics Test, delivering rapid drug-gene interaction data through its precision medicine platform, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, remains cautious on Tempus AI after the recent decline. He notes that persistent downside momentum across all major moving averages shows technical weakness. The $1.5 billion Personalis deal adds long-term uncertainty and may overburden the balance sheet if integration issues arise. Technical signals, including a low RSI and negative Bull/Bear Power, underscore a strong bearish backdrop. Kharitonov warns, "I see little evidence of a reversal — traders should avoid premature entries while the risk of further selling prevails."

Viktoras Karapetjanc, expert at Traders Union, highlights opportunity in Tempus AI’s strategic acquisition and product expansion. He sees the Personalis deal as a catalyst to strengthen data profiling and drive future growth. The recently launched OneOme 27-Gene Test positions the company well in precision medicine. Karapetjanc believes the market could reward these moves once sentiment turns. He states, "With these developments, further growth is likely if momentum stabilizes above key resistance."

Parshwa Turakhiya, analyst, notes that TEM is under sustained bearish pressure, with price action stuck below all major averages. He sees oversold technical signals and high intraday volatility creating near-term setups for active traders. The $46.53–$47.43 zone is pivotal for momentum shifts. Turakhiya concludes, "Short-term, I’ll be watching for sharp reversals or breakdowns around these levels — the setup favors nimble trading over conviction holds."

Bearish momentum confirmed as key averages and signals turn negative

TEM is trading below its 20-day, 50-day, and 200-day moving averages at $56.14, $51.4, and $61.44, confirming active downside momentum in short-, medium-, and long-term trends. The nearest support sits at $46.53 and resistance at $47.43. Momentum signals are weak, with the MACD at neutral, ADX indicating a sell, and RSI at 40.9 highlighting further sell pressure. Both Stochastic RSI and Commodity Channel Index signal oversold conditions. Bull/Bear Power at -4.34 confirms sellers are dominating intraday, and the Awesome Oscillator also shows strong bearish pressure. TEM declined by $1.72, or 3.51%, after a downside gap, with price hovering mid-range amid 4.34% intraday volatility. Overall, the tone remains bearish post-open in line with prevailing momentum signals.

Earlier, analysts noted that the rapid growth of AI-driven companies has intensified debate over wealth concentration and the distribution of gains within the sector. The current technical weakness in Tempus AI highlights the ongoing challenges facing newly public AI firms, with downside risk remaining elevated as the price approaches key support levels.

Source of Data: TEM Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.